Immune checkpoint inhibitor therapy for hepatocellular carcinoma

Liver cancer is the third most common cause of cancer-associated death. Advances in the last decade have provided more options for treating hepatocellular carcinoma. The use of immune checkpoint inhibitors represents a leap forward and broadens the armamentarium for clinicians. In this article, we p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramai, Daryl, Shapiro, Alexandra, Facciorusso, Antonio, Bareggi, Claudia, Gambini, Donatella, Rijavec, Erika, Tomasello, Gianluca, Galassi, Barbara, Ghidini, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648525/
https://www.ncbi.nlm.nih.gov/pubmed/36406972
http://dx.doi.org/10.20524/aog.2022.0746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648525/
https://www.ncbi.nlm.nih.gov/pubmed/36406972
http://dx.doi.org/10.20524/aog.2022.0746

Ejemplares similares